{"title":"Prevalence and predictors of viral load suppression in adults living with HIV in the western region of Ghana: A cross-sectional study.","authors":"Philip Boakye, Adwoa Safowaa","doi":"10.3934/publichealth.2023033","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although antiretroviral therapy is beneficial and available free of cost to patients, several roadblocks still prevent patients from reaching viral suppression. This research aimed to determine the prevalence rate of viral suppression among people living with HIV in the western region of Ghana and identify the factors contributing to viral non-suppression.</p><p><strong>Methods: </strong>A cross-sectional study was conducted on 7199 HIV-positive adults. All data from the Sekondi Public Health Laboratory database was exported to Microsoft Excel and then verified and filtered before being exported to STATA 16.1. Viral non-suppression was modeled statistically using logistic regression.</p><p><strong>Results: </strong>Viral load suppression was achieved in 5465 (75.91%) study participants who received antiretroviral treatment. However, 1734 participants (24.0%) did not achieve viral suppression. Patients with poor adherence to ARV (AOR 0.30; 95% CI 0.16, 0.58) and fair adherence to ARV (AOR 0.23; 95% CI 0.12, 0.45) were associated with a lower odd of viral non-suppression. Patients with six (6) months to two (2) years of treatment before viral load testing (AOR 0.67; 95% CI 0.46, 0.98) were also associated with a lower likelihood of viral non-suppression.</p><p><strong>Conclusions: </strong>The rate of non-suppression was high, and the suppression rate fell short of the UNAIDS target. Poor ARV adherence, fair ARV adherence, and a treatment duration of six (6) months to two (2) years before viral load testing appear to be obstacles to viral load suppression. The research findings seem to suggest that viral load testing supports viral non-suppression. Therefore, using viral load tests to monitor medication's effects on health can motivate patients to adhere to their prescribed medication regimen. More research is needed to determine whether viral load testing can improve adherence. Given the high rate of virologic failure, the study highlights the importance of identifying antiretroviral resistance patterns.</p>","PeriodicalId":45684,"journal":{"name":"AIMS Public Health","volume":"10 2","pages":"469-479"},"PeriodicalIF":3.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251059/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIMS Public Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3934/publichealth.2023033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Although antiretroviral therapy is beneficial and available free of cost to patients, several roadblocks still prevent patients from reaching viral suppression. This research aimed to determine the prevalence rate of viral suppression among people living with HIV in the western region of Ghana and identify the factors contributing to viral non-suppression.
Methods: A cross-sectional study was conducted on 7199 HIV-positive adults. All data from the Sekondi Public Health Laboratory database was exported to Microsoft Excel and then verified and filtered before being exported to STATA 16.1. Viral non-suppression was modeled statistically using logistic regression.
Results: Viral load suppression was achieved in 5465 (75.91%) study participants who received antiretroviral treatment. However, 1734 participants (24.0%) did not achieve viral suppression. Patients with poor adherence to ARV (AOR 0.30; 95% CI 0.16, 0.58) and fair adherence to ARV (AOR 0.23; 95% CI 0.12, 0.45) were associated with a lower odd of viral non-suppression. Patients with six (6) months to two (2) years of treatment before viral load testing (AOR 0.67; 95% CI 0.46, 0.98) were also associated with a lower likelihood of viral non-suppression.
Conclusions: The rate of non-suppression was high, and the suppression rate fell short of the UNAIDS target. Poor ARV adherence, fair ARV adherence, and a treatment duration of six (6) months to two (2) years before viral load testing appear to be obstacles to viral load suppression. The research findings seem to suggest that viral load testing supports viral non-suppression. Therefore, using viral load tests to monitor medication's effects on health can motivate patients to adhere to their prescribed medication regimen. More research is needed to determine whether viral load testing can improve adherence. Given the high rate of virologic failure, the study highlights the importance of identifying antiretroviral resistance patterns.
背景:尽管抗逆转录病毒治疗对患者是有益的,并且可以免费获得,但仍有一些障碍阻碍患者达到病毒抑制。本研究旨在确定加纳西部地区艾滋病毒感染者中病毒抑制的流行率,并确定导致病毒不抑制的因素。方法:对7199例hiv阳性成人进行横断面调查。Sekondi公共卫生实验室数据库中的所有数据导出到Microsoft Excel中,然后进行验证和过滤,然后导出到STATA 16.1。采用逻辑回归对病毒无抑制进行统计建模。结果:5465名(75.91%)接受抗逆转录病毒治疗的研究参与者实现了病毒载量抑制。然而,1734名参与者(24.0%)没有达到病毒抑制。抗逆转录病毒药物依从性差的患者(AOR 0.30;95% CI 0.16, 0.58)和ARV的公平依从性(AOR 0.23;95% CI 0.12, 0.45)与较低的病毒不抑制奇数相关。接受6个月至2年治疗后进行病毒载量检测的患者(AOR 0.67;95% CI 0.46, 0.98)也与较低的病毒不抑制可能性相关。结论:未抑制率较高,抑制率未达到联合国艾滋病规划署的目标。抗逆转录病毒药物依从性差,抗逆转录病毒药物依从性一般,以及在病毒载量检测前的6个月至2年的治疗时间似乎是抑制病毒载量的障碍。研究结果似乎表明,病毒载量测试支持病毒非抑制。因此,使用病毒载量测试来监测药物对健康的影响可以激励患者坚持他们的处方药物治疗方案。需要更多的研究来确定病毒载量检测是否可以提高依从性。鉴于病毒学失败率很高,该研究强调了确定抗逆转录病毒耐药性模式的重要性。